To analyze their relative effects on premenopausal bone mass, we have studied the impact of lifelong estrogen exposure, assessed by an estrogen score (ES; computed on age at menarche, average length of menstrual cycles since menarche, and use of birth control pills), heredity, and some environmental factors on vertebral bone density (VBD), of 63 premenopausal women (age, 19-40 yr). Compared with women with normal bone density (Z score > -1), subjects with low VBD (Z score < - Postmenopausal bone mineral density is dependent on both the amount ofbone mass accumulated during infancy and adolescence and the rate of bone loss that occurs with menopause and aging (1). Since pharmacological interventions currently in vogue for the treatment of established osteoporotic syndromes can only maintain bone mass, or at best achieve modest transient increases (2-4), prevention ofbone loss with early intervention currently appears to be the best strategy for the management of osteoporosis. In fact, osteoporosis prevention programs could be directed not only to reduce the rapid bone loss that follows menopause but also to potentiate the accumulation of bone mass during infancy through early adulthood. Ideally, the achievement of an adequate peak bone mass at skeletal maturity should constitute the best protection against potential future bone loss. Hence, the identification of factors that influence the development of optimal bone density are of utmost importance, since this information may aid researchers and clinicians to devise the most appropriate strategies for maximizing bone mass in the developmental period. Both genetic and environmental factors have been invoked as determinants ofpeak bone mass (5-8, 11, 14, 15, 32, 37). A relevant role of heredity has been recently underscored by observations of reduced bone densities in daughters of women with osteoporosis compared with those of normal mothers (6) and from twin studies showing greater concordance in bone densities between monozygotic than dizygotic twins (7, 8) . Since this concordance decreases as the twin pairs age, it appears that factors related to the environment play an increasingly important role as aging ensues. Postmenopausal bone loss is clearly related to estrogen deficiency (9) and can be prevented by estrogen replacement (3) 
Introduction
To analyze their relative effects on premenopausal bone mass, we have studied the impact of lifelong estrogen exposure, assessed by an estrogen score (ES; computed on age at menarche, average length of menstrual cycles since menarche, and use of birth control pills), heredity, and some environmental factors on vertebral bone density (VBD), of 63 premenopausal women (age, 19-40 yr) . Compared with women with normal bone density (Z score > -1), subjects with low VBD (Z score < -1) had significantly lower ES (15.1±3.9 vs. 18.7±2.4, P = 0.001), higher age at menarche (13.8±1.7 vs. 12.6±1.4 yr, P = 0.005), and lower serum estradiol (46.9±37 vs. 86.6±57 pg/ml, P = 0.023) and estrone levels (107.4±60 vs. 178.8±9.0 pg/ml, P = 0.05). Likewise, women in the lowest quartile for VBD had significantly lower ES (15.3±4.5 vs. 18.1±2.7, P =0.006) and higher age at menarche (13.9±1.9 vs. 12.8±.4, P = 0.02) than those in the upper three quartiles. A higher proportion of subjects with irregular menses (52 vs. 23%, P = 0.03) and a positive family history of osteoporosis (86 vs. 61%, P = 0.04) was found in the low VBD group compared with subjects with normal VBD. VBD correlated positively with ES (r = 0.44, P = < 0.001) and negatively with age at menarche (r = -0.30, P = 0.03) by simple linear regression, whereas no correlation was found between VBD and age, body mass index, parity, lactation, physical activity, sunlight exposure, and dietary calcium and vitamin D intakes. The correlation between VBD and ES improved after correcting for the effect ofall the other variables by partial correlation analysis (Pearson partial r = 0.57, P = < 0.01), which also disclosed a significant contribution of dietary calcium to VBD. However, ES was the only significant independent determinant of VBD, by stepwise multiple regression analysis (R2 = 0.24). Therefore, premenopausal estrogen exposure, and possibly genetic predisposition, rather than environmental factors, are the major determinants for the development of peak bone mass before menopause. (J. Clin. Invest. 1992.90:2464-2471.) Key words: bone density * osteoporosis. menstrual cycle * menarche * menopause Postmenopausal bone mineral density is dependent on both the amount ofbone mass accumulated during infancy and adolescence and the rate of bone loss that occurs with menopause and aging (1) . Since pharmacological interventions currently in vogue for the treatment of established osteoporotic syndromes can only maintain bone mass, or at best achieve modest transient increases (2) (3) (4) , prevention ofbone loss with early intervention currently appears to be the best strategy for the management of osteoporosis. In fact, osteoporosis prevention programs could be directed not only to reduce the rapid bone loss that follows menopause but also to potentiate the accumulation of bone mass during infancy through early adulthood. Ideally, the achievement of an adequate peak bone mass at skeletal maturity should constitute the best protection against potential future bone loss. Hence, the identification of factors that influence the development of optimal bone density are of utmost importance, since this information may aid researchers and clinicians to devise the most appropriate strategies for maximizing bone mass in the developmental period.
Both genetic and environmental factors have been invoked as determinants ofpeak bone mass (5-8, 11, 14, 15, 32, 37) . A relevant role of heredity has been recently underscored by observations of reduced bone densities in daughters of women with osteoporosis compared with those of normal mothers (6) and from twin studies showing greater concordance in bone densities between monozygotic than dizygotic twins (7, 8) . Since this concordance decreases as the twin pairs age, it appears that factors related to the environment play an increasingly important role as aging ensues. Postmenopausal bone loss is clearly related to estrogen deficiency (9) and can be prevented by estrogen replacement (3); therefore, one can speculate that in females estrogens may play a functional role in the achievement and maintenance of bone mass during the fertile period. Since information on the role ofestrogens in premenopausal women is still scanty and inconclusive (10) (11) (12) Estrogen exposure. To quantitate a woman's lifelong exposure to estrogen, a scoring system was developed by modifying the method described by Dhuper et al. ( 13) . This estrogen score (ES) is based on the three main physiological and environmental factors that affect the estrogen status of a fertile woman: duration of the fertile period (expressed as age at menarche), length and frequency of menstrual cycles, and use of birth control medications. Weighted scores were assigned for each factor as shown in Table I . Accordingly, each individual could score between 2 and 24 points. A normal menstrual cycle (eumenorrhea) was defined as the occurrence of 9-13 menses/yr. Between three and eight menses/yr was considered oligomenorrhea and less than three menses/yr was considered amenorrhea. Accordingly, a subject was classified as having had menstrual irregularities when at least one episode of either oligomenorrhea or amenorrhea was reported during the fertile period. However, for the ES, periods or transient oligomenhorrhea and amenorrhea were scored according to the total duration for each subject's fertile period (Table I ). Age at menarche and menstrual cycles were considered the major determinants of a woman's overall estrogen exposure and, thus, they were given the greatest weight. Since available data are inconclusive as to whether oral contraceptives have a significant impact on bone density ( 14-17) the use of birth control pills was given a lower weight in our scoring system, although scores were adjusted for the duration of use.
Dietary intake. Assessment of dietary habits was performed by a registered dietitian using the cross-check method ( 18) . The subjects were asked to indicate weekly frequency of consumption of certain food products. Records of a typical daily intake were then used to cross-check the food frequency data. They were entered in a database and elaborated by a computer program (IPC data diet, San Jose, CA), which calculates the relative content of each dietary element from a 1. Abbreviations used in this paper: BMI, body mass index; El, estrone; E2, estradiol; ES, estrogen score; VBD, vertebral bone density. typical daily diet. The average daily intake of calcium and vitamin D were recorded. Sunlight exposure. Information on sunlight exposure was obtained through a questionnaire and expressed as outdoor score using a method described previously ( 18 ) . Briefly, the subjects were asked how much time they spent outdoors in direct sunlight from 0900-1600, during 1 d in the different seasons ofthe year. Scores were assigned as follows: not at all in any season, 0; < 30 min: winter, 0; spring, 2; fall, 2; summer, 4; > 30 min: winter, 1; spring, 3; fall, 3; summer, 5. The sum ofthe points obtained for the four seasons (0-12 ) constituted the outdoor score.
Bone densitometry. Vertebral bone density (VBD) was measured by quantitative computed tomography ofthe vertebral bodies ofT 12 to L3, using a scanner (GE 9800) (19, 20) . The coefficient of variation is 4.5% in our center (20) . VBD values were expressed either in milligrams per cubic centimeter, or as Z scores, computed based on the data from 538 normal nonblack women ( 19) aged 20-80 yr, to indicate the deviation from the expected average values for sex-and age-matched normals.
Biochemical tests. Serum alkaline phosphatase and calcium, and urine calcium and creatinine tests, were performed using standard autoanalyzer techniques. Serum 25 (OH) D was measured by a competitive protein-binding radioassay (21 ) . Serum estrone (El ) and estradiol (E2) were measured using radioimmunoassay techniques (SmithKline Beecham Laboratories, Van Nuys, CA). Since serum samples for El and E2 were drawn at the time each subject presented for evaluation, El and E2 values are not related to a specific phase of the menstrual cycle.
Statistical analysis. Statistical analysis was performed using Statgraphics (version 5.0; STSC Inc., Rockville, MD). Data were managed using Lotus 1-2-3 (version 2.0; Lotus Development Corp., Cambridge, MA). Results are expressed as mean±standard deviation. The interactions between age, BMI, ES, E 1, E2, age of menarche, number of preg- Stepwise multiple regression analysis was used to assess the independent contribution of each variable to bone density.
Results
Initially, the effect of age on bone density and the other variables was studied. To this end, the study population was divided into four 5-yr groups (Table II) and the data were analyzed by one-way analysis of variance. No significant differences were observed across the age groups for all parameters, with the exception ofphysical activity score and lactation. Multiple-range test disclosed a significantly lower level ofactivity in the youngest women and a higher number of years oflactation in the 31-35-yr-old subjects. However, the former finding may only reflect a sample bias because of the limited number of subjects included in the first group. Interestingly, the average bone mineral density was not different across the four age groups. Accordingly, no correlation was found between age and VBD by linear regression (r < 0.10) (Fig. 1 ). Although this result would rule out significant age-related changes in bone mass in this cohort, the subsequent analyses were still performed on data normalized to the age-and sex-adjusted expected average VBD. To identify potential factors that can contribute to premenopausal bone mass, the population was stratified according to VBD Z scores using two approaches. First, two groups were generated using a cut-off value of 1 SD below the age-adjusted average bone density. By this method the population was divided approximately at the lower third. Thus, the group with normal bone density (Z score > -1) was about twice as large as the low bone density group (Z score < -1; Table III) . No significant differences were observed in age, body mass, physical activity, sunlight exposure, nutritional habits, and biochemical indices. However, there was a significantly higher proportion ofsubjects with positive family history ofosteoporosis in the low bone density group. Furthermore, the latter group had an average lower estrogen score, higher age at menarche, higher incidence of irregular menses, and lower random E2 and El levels (Table IV) . On the other hand, years of use of birth control pills, parity, and average duration oflactation per woman were not different between the two groups.
As a second approach, the study population was stratified in quartiles based on VBD Z scores. This method produces four groups of equal numbers. Results closely similar to those just described were obtained by analysis of variance of each variable. Accordingly, a positive family history of osteoporosis was more common in the lower quartiles and less common in the higher quartiles (Table V) . In particular, the incidence of familiarity was significantly higher in subjects in the lowest quartile than in the pooled quartiles 2-4, whereas no difference was observed for any of the anthropometric, lifestyle, dietary, and biochemical parameters. Also, subjects in the lowest quartile had a significantly lower ES compared with those in both the highest quartile and the upper three quartiles combined (Table VI) . Subjects in the lowest quartile also had a higher age at menarche than the average of all other subjects. Although the average serum estrogen levels tended to increase with increasing quartiles, the changes did not reach statistical significance, except for serum E 1, which was higher in quartile 4 than in any other groups. To further investigate the factors contributing to premenopausal bone mass, data on continuous variables were analyzed by simple and multiple-regression analyses. Considering the whole population, we found a significant positive correlation between VBD and estrogen score (r = 0.44, P < 0.001; Fig. 2 ) and an inverse correlation between VBD and age at menarche (r = -0.30, P = 0.03; Fig. 3 ) by simple linear regression. Significant positive correlations were also observed for serum E2 (r = 0.50, P = 0.02) and El (r = 0.48, P = 0.03), although data from only 21 patients were available. On the other hand, no relationship was found between VBD and all the other parameters studied.
Data on a subset of 39 subjects, whose values on the most relevant parameters studied were complete, were analyzed further. The strong correlation between ES and VBD was confirmed in this subgroup by both simple regression and partial correlation analyses, which corrects for the interaction of any other variable included in the analysis (Table VII) 
Discussion
The present results support the hypothesis that estrogen exposure is the main factor determining bone mass in premenopausal women. Our data also suggest that genetic potential has a relatively higher weight than environmental factors in the development of premenopausal bone mass.
Other reports have also underscored the role of hormonal homeostasis in the acquisition and preservation of bone mass (22-24). Cann et al. (22) found that menstrual history is the best predictor of trabecular bone density in premenopausal women and that primary amenorrheic women have reduced bone densities compared with women with secondary amenorrhea (23), indicating that even transient or interrupted exposure to physiological levels of circulating estrogen is certainly better than total lack of sexual hormones. Along this line, Drinkwater et al. (24) recently observed lower bone densities in athletes with oligomenorrhea or amenorrhea as compared with eumenorrheic subjects, with the amenorrheic athletes having the most severe reduction in bone density. In our study, menstrual irregularities were found to be more frequent in women with lower bone mass, suggesting that periods of oligo- menorrhea and amenorrhea also represent states of transient Thus, achieving sexual maturity earlier in life appears to be an hypoestrogenism, which, if protracted long enough, might eiadditional factor conditioning the exposure of the skeletal tisther interfere with normal skeletal maturation or produce subsue to the beneficial effects of estrogen. tle bone loss that may not be reversible. In a previous study, Integrating these two physiological events (i.e., characterisPrior et al. (25 ) observed that anovulatory cycles and defects in tics of menstrual cycles and age at menarche), along with the the luteal phase could exist even in the presence of normal use of birth control pills, into an ES further evidenced the cycle length and that these asymptomatic disturbances may be weight of estrogen exposure on premenopausal bone mass. ES associated with significant bone loss, thus suggesting that not was highly correlated with VBD and, in the multiple-regression only estrogen but progesterone levels may be important for the analysis, it was the most important independent contributor to maintenance of a normal skeletal homeostasis. These observa-VBD variability. Similar results were obtained in younger adotions further underscore the importance ofintact ovarian funclescent females in whom wrist and spine bone densities position for an adequate premenopausal bone mass. On the other tively correlated with estrogen status, estimated by a score simihand, although hormonal replacement therapy in early postlar to ours ( 13 ) . In that study the use ofbirth control pills was menopausal women has been documented to prevent rapid given a heavier weight in the estimate of ES than in our study. bone loss (3), whether the resumption of normal menses in However, although a few reports have established a positive women with temporary but substantially long oligomenorrelationship between bone density and the use of oral contrarhea/amenorrhea is sufficient to counterbalance the negative ceptives (15, 17) , in another study such a correlation was not effect of transient hypoestrogenism within the fertile period evident (16) . Besides the different doses of active compounds remains to be determined (26, 27) . present in different birth control preparations, one possible exOur cross-sectional analysis also revealed an inverse relaplanation for these inconsistent results might stem from the tionship between VBD and age at menarche, an observation fact that exogenous estrogen may suppress endogenous producalso reported by others (13, 28) . In our population, women tion, so that circulating levels of active hormones may not be with normal bone density had their first menstrual period an excessively high (29) . In addition, orally administered estrogen average 14 mo earlier than women with low bone density.
undergoes rapid hepatic degradation and loss of activity (30), (10) (11) (12) . Our data are consistent with this notion, but they are limited by the fact that hormone levels were obtained randomly during the menstrual cycle, thus they may not be representative of the overall ovarian function of each subject. On the other hand, Dhuper et al. ( 13 ) did not find a significant correlation between bone mass and serum estrogen levels measured in a pooled sample of blood obtained at four different days during the cycle. In any case, because of the intrinsic wide variability in the different phases of the menstrual cycle, a single random serum estrogen level has obvious limited value for any diagnostic use for early detection of low bone mass in premenopausal women.
The present study also underscores the role of heredity on bone mass development. Premenopausal women with low bone mass had a positive maternal family history ofosteoporosis more frequently than subjects with normal bone mass. This Age at menarche Figure 3 . Correlation between vertebral bone density, expressed as Z score, and age at menarche in 58 premenopausal Caucasian women. The regression line and 95% confidence interval are also illustrated. (34, 35) . Likewise, although we did not find a strong contribution of body mass to bone density, heavier subjects have been reported to have denser bones than individuals with lower body mass ( 13, 36) . However, the effect of body size on skeletal maturation and health may also be mediated by hormonal, as well as mechanical effects. Overweight individuals tend in fact to have higher estrogen levels (36) , which may add to the positive effect of weight bearing on bone density. Finally, our data do not reveal significant age-related changes in bone density between 20 and 40 yr ofage. This is in agreement with previous studies (28, 37) and may simply reflect the lack of power of cross-sectional observations to detect subtle historical trends, such as those leading to a premenopausal peak of bone mass. Alternatively, the results may indicate that between 20 and 40 yr of age there is no significant increase ofbone density and that a peak is reached earlier. The answer to this question can be obtained only through longterm longitudinal analyses.
The notion that in some otherwise healthy women bone density is lower than average well before menopause occurs implies that a certain number of cases diagnosed as postmenopausal osteoporosis may in fact be cases ofwomen whose bone density was low before menopause and came to medical observation only after the cessation of menses, perhaps because ofa vertebral fracture. Thus, a low bone mass in an early postmenopausal woman should not necessarily be interpreted to indicate rapid bone loss. Careful evaluation of a patient's past history with respect to menstrual history and familiarity of osteoporosis is very helpful and should always be considered a major point in the diagnostic process ofpostmenopausal women with low bone mass. If these assumptions are confirmed in larger, prospective studies, revision of the current etiologic classification of osteoporosis should be considered to indicate that type 1 (or postmenopausal) osteoporosis may be the consequence of either fast bone loss or low peak bone mass.
In conclusion, the present study demonstrates that estrogen status is the most important determinant of premenopausal bone mass. Other factors, such as body mass, dietary habits, physical activity, and sunlight exposure, appear to have less impact. A thorough assessment ofmenstrual history may therefore help in the evaluation of bone health in premenopausal women. Thus, young Caucasian females with a positive family history ofosteoporosis and with signs and symptoms suggestive of hormonal imbalance should be considered for screening for osteopenia and advised for possible intervention after menopause. Efforts directed toward the preservation of bone mass and the prevention of bone loss should be initiated as early as possible.
